SCHEMBL980924

SCHEMBL980924

COc1cccc(C#Cc2nc(C)n(-c3cc[nH]c(=O)c3)c2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
GRM5 P41594 7/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
KCNH2 Q12809 2/20 0.41
ADRB3 P13945 1/20 0.41
TSPO P30536 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
GPR35 Q9HC97 1/20 0.41
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HAO1 Q9UJM8 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP2 O95551 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980911 0.87 GRM5 (0.41) GRM5SMN1; SMN2KCNH2ADRB3TSPO
SCHEMBL981471 0.85 GRM5 (0.44) CYP1A2GRM5KCNH2ADRB3TSPO
SCHEMBL6864903 0.85 GRM5 (0.42) GRM5SMN1; SMN2KCNH2ADRB3TSPO
SCHEMBL12948767 0.78 CYP1A2 (0.49) CYP1A2SMN1; SMN2LMNATSHRMEN1
SCHEMBL980901 0.78 GRM5 (0.65) GRM5KCNH2ADRB3TSPOTMEM97
SCHEMBL978638 0.70 GRM5 (0.42) GRM5KCNH2ADRB3TSPOTMEM97
SCHEMBL983162 0.68 GRM5 (0.44) CYP1A2GRM5KCNH2ADRB3TSPO
SCHEMBL978610 0.68 GRM5 (0.47) GRM5KCNH2ADRB3TSPOTMEM97
SCHEMBL980914 0.67 PDE3B (0.37) SMN1; SMN2LMNAALDH1A1MAPT
SCHEMBL12948765 0.66 XDH (0.41) SMN1; SMN2TSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
EP-2456765-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-05-30 EP disclosed
WO-2011006910-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 WO disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015202-A1 IMIDAZOLES GRM5, GRM1, GRIK5 CYP1A2 1068/4885GRM5 1/4885SMN1; SMN2 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.